tetano
Editor, Senior Moderator
J Infect Dis
. 2025 Dec 3:jiaf605.
doi: 10.1093/infdis/jiaf605. Online ahead of print. Improved immune response against influenza A viruses with receipt of a recombinant influenza vaccine in healthcare personnel with prior low antibody response to egg-based influenza vaccines, Israel, 2019-20
Kelsey M Sumner[SUP] 1 [/SUP], Mark Katz[SUP] 2 3 [/SUP], Avital Hirsch[SUP] 2 [/SUP], Alon Peretz[SUP] 4 [/SUP], David Greenberg[SUP] 5 [/SUP], Emily T Martin[SUP] 3 [/SUP], Rachel Truscon[SUP] 3 [/SUP], Laura J Edwards[SUP] 6 [/SUP], Lauren Grant[SUP] 1 [/SUP], Emma K Noble[SUP] 1 [/SUP], Gabriella Newes-Adeyi[SUP] 6 [/SUP], Jacob Dreiher[SUP] 5 [/SUP], Alicia Fry[SUP] 1 [/SUP], Brendan Flannery[SUP] 1 [/SUP], Eduardo Azziz-Baumgartner[SUP] 1 [/SUP], Arnold S Monto[SUP] 3 [/SUP], Min Z Levine[SUP] 1 [/SUP], Mark Thompson[SUP] 7 [/SUP], Ran Balicer[SUP] 2 [/SUP], Ashley Fowlkes[SUP] 1 [/SUP]
Affiliations
Background: Adult studies have shown that quadrivalent recombinant influenza vaccines (RIV4) induce a higher antibody response than quadrivalent egg-based inactivated influenza vaccines (IIV4).
Methods: Healthcare personnel (HCP) from a 2018-19 cohort study that assessed IIV4 immunogenicity in Israel were recruited into a 2019-20 randomized trial of RIV4 and IIV4. 2018-19 low titer low responders (LTLRs) had pre-vaccination hemagglutination inhibition antibody titers ≤1:40 and <4-foldrise post-vaccination. We assessed whether RIV4 versus IIV4 receipt in the 2019-20 season improved response among 2018-19 LTLRs using logistic regression adjusted for employment hospital.
Results: Of 228 HCP classified as 2018-19 LTLRs, 2019-20 RIV4 recipients were 3.6 (95% CI: 1.2-11.4) and 8.3 (95% CI: 3.0-26.3) times as likely to become a non-LTLR against influenza A(H1N1)pdm09 and cell-derived A(H3N2) vaccine components compared to IIV4 recipients.
Conclusions: RIV4 had improved immunogenicity against influenza A viruses among previously classified low vaccine responder HCP, highlighting how recombinant influenza vaccines could improve antibody responses against influenza A for HCP at risk for poor influenza antibody response.
Keywords: Influenza vaccines; antibody response; recombinant vaccines.
. 2025 Dec 3:jiaf605.
doi: 10.1093/infdis/jiaf605. Online ahead of print. Improved immune response against influenza A viruses with receipt of a recombinant influenza vaccine in healthcare personnel with prior low antibody response to egg-based influenza vaccines, Israel, 2019-20
Kelsey M Sumner[SUP] 1 [/SUP], Mark Katz[SUP] 2 3 [/SUP], Avital Hirsch[SUP] 2 [/SUP], Alon Peretz[SUP] 4 [/SUP], David Greenberg[SUP] 5 [/SUP], Emily T Martin[SUP] 3 [/SUP], Rachel Truscon[SUP] 3 [/SUP], Laura J Edwards[SUP] 6 [/SUP], Lauren Grant[SUP] 1 [/SUP], Emma K Noble[SUP] 1 [/SUP], Gabriella Newes-Adeyi[SUP] 6 [/SUP], Jacob Dreiher[SUP] 5 [/SUP], Alicia Fry[SUP] 1 [/SUP], Brendan Flannery[SUP] 1 [/SUP], Eduardo Azziz-Baumgartner[SUP] 1 [/SUP], Arnold S Monto[SUP] 3 [/SUP], Min Z Levine[SUP] 1 [/SUP], Mark Thompson[SUP] 7 [/SUP], Ran Balicer[SUP] 2 [/SUP], Ashley Fowlkes[SUP] 1 [/SUP]
Affiliations
- PMID: 41330417
- DOI: 10.1093/infdis/jiaf605
Background: Adult studies have shown that quadrivalent recombinant influenza vaccines (RIV4) induce a higher antibody response than quadrivalent egg-based inactivated influenza vaccines (IIV4).
Methods: Healthcare personnel (HCP) from a 2018-19 cohort study that assessed IIV4 immunogenicity in Israel were recruited into a 2019-20 randomized trial of RIV4 and IIV4. 2018-19 low titer low responders (LTLRs) had pre-vaccination hemagglutination inhibition antibody titers ≤1:40 and <4-foldrise post-vaccination. We assessed whether RIV4 versus IIV4 receipt in the 2019-20 season improved response among 2018-19 LTLRs using logistic regression adjusted for employment hospital.
Results: Of 228 HCP classified as 2018-19 LTLRs, 2019-20 RIV4 recipients were 3.6 (95% CI: 1.2-11.4) and 8.3 (95% CI: 3.0-26.3) times as likely to become a non-LTLR against influenza A(H1N1)pdm09 and cell-derived A(H3N2) vaccine components compared to IIV4 recipients.
Conclusions: RIV4 had improved immunogenicity against influenza A viruses among previously classified low vaccine responder HCP, highlighting how recombinant influenza vaccines could improve antibody responses against influenza A for HCP at risk for poor influenza antibody response.
Keywords: Influenza vaccines; antibody response; recombinant vaccines.